---
title: "RYTM.US (RYTM.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/RYTM.US/news.md"
symbol: "RYTM.US"
name: "RYTM.US"
parent: "https://longbridge.com/zh-HK/quote/RYTM.US.md"
datetime: "2026-03-12T18:13:30.281Z"
locales:
  - [en](https://longbridge.com/en/quote/RYTM.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RYTM.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RYTM.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/RYTM.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/RYTM.US/news.md)


# RYTM.US (RYTM.US) — 相關新聞

### [A Look At Rhythm Pharmaceuticals (RYTM) Valuation After New Trial Data Earnings And Financing Updates](https://longbridge.com/zh-HK/news/278455981.md)
*2026-03-09T22:32:19.000Z*
> Rhythm Pharmaceuticals (RYTM) is gaining investor attention following positive Phase 3 trial data for setmelanotide in a

### [Top Rhythm Pharma Insider Executes Significant Stock Sale Move](https://longbridge.com/zh-HK/news/278190908.md)
*2026-03-07T02:13:16.000Z*
> Rhythm Pharmaceuticals' Corporate Controller, Christopher Paul German, sold 5,614 shares valued at $502,789 on March 6, 

### [Rhythm Pharmaceuticals Discloses 18.8% BMI Drop In Rare Obesity Patients](https://longbridge.com/zh-HK/news/277486755.md)
*2026-03-02T14:41:00.000Z*
> Rhythm Pharmaceuticals (NASDAQ:RYTM) reported an 18.8% placebo-adjusted BMI reduction in patients from its Phase 3 TRANS

### [Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity](https://longbridge.com/zh-HK/news/277458059.md)
*2026-03-02T11:44:45.000Z*
> Rhythm Pharmaceuticals reported positive Phase 3 results for setmelanotide in hypothalamic obesity, showing an 18.8% pla

### [Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential](https://longbridge.com/zh-HK/news/277393651.md)
*2026-03-02T02:37:13.000Z*
> Rhythm Pharmaceuticals is approaching a crucial FDA decision for IMCIVREE in acquired hypothalamic obesity, with plans f

### [Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026](https://longbridge.com/zh-HK/news/277365021.md)
*2026-03-01T17:31:29.000Z*
### [Rhythm Pharma: Positive data from Phase 3 trial of Setmelanotide: 18.8% BMI reduction difference in all 142 patients. PDUFA goal date: March 20, 2026.](https://longbridge.com/zh-HK/news/277365418.md)
*2026-03-01T17:31:23.000Z*
> A BMI reduction of 18.8% compared to the placebo was observed in a group of 142 patients over 52 weeks. This group inclu

### [Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity | RYTM Stock News](https://longbridge.com/zh-HK/news/277365135.md)
*2026-03-01T09:30:00.000Z*
> Rhythm Pharmaceuticals announced positive results from its Phase 3 TRANSCEND trial of setmelanotide for acquired hypotha